PTPI Petros Pharmaceuticals, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1815903 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-12.2%
TTM net income YoY-75.4%
TTM EPS YoY-1,214.5%
Revenue 3-yr CAGR-13.2%
Net income 3-yr CAGR—
Margins
Gross margin76.3%
Operating margin-90.5%
Net margin-280.1%
FCF margin—
EBITDA margin-35.1%
Returns
ROE-622.1%
ROA-64.5%
ROIC (approx.)—
Asset turnover0.23x
Leverage & solvency
Liabilities / assets170.2%
Debt / equity—
Current ratio0.40x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.18x
Accruals ratio-52.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | $5.11M | $5.82M | $5.99M | $7.81M |
| Cost of revenue | — | $1.21M | $1.63M | $2.29M | $1.60M |
| Gross profit | — | $3.90M | $4.19M | $3.70M | $6.21M |
| R&D expense | — | $2.62M | $2.41M | $1.74M | $1.79M |
| SG&A expense | $4.64M | $4.63M | $9.26M | $12.21M | $15.59M |
| Operating income | -$4.64M | -$4.63M | -$13.62M | -$19.92M | -$18.05M |
| Interest expense | — | $560,909 | $536,138 | $596,018 | $368,660 |
| Pretax income | -$4.50M | -$705,174 | -$8.16M | -$20.04M | -$8.99M |
| Income tax | $0 | $0 | $0 | — | $0 |
| Net income | $1.91M | -$14.32M | -$8.16M | -$20.04M | -$8.99M |
| EBITDA | — | -$1.80M | -$10.33M | -$14.32M | -$11.17M |
| EPS (basic) | -1.56 | -83.47 | -6.35 | -9.68 | -8.25 |
| EPS (diluted) | -1.56 | -83.47 | -6.35 | -9.68 | -8.25 |
| Weighted avg. shares (diluted) | 28.07M | 321,042 | 2.18M | 2.07M | 1.09M |
| Banking | |||||
| Net interest income | $256,933 | $371,769 | $515,311 | $14,194 | — |
| Balance sheet | |||||
| Cash & equivalents | $5.14M | $1.72M | $13.34M | $9.43M | $23.85M |
| Receivables | — | $416,076 | $2.23M | $2.11M | $2.46M |
| Inventory | — | $1.35M | $1.61M | $1.82M | $519,649 |
| Current assets | $5.16M | $7.29M | $20.39M | $14.67M | $30.54M |
| PP&E, net | — | $22,948 | $28,957 | $39,177 | $49,397 |
| Intangibles | — | $3.20M | $8.97M | $12.24M | $25.29M |
| Total assets | $5.16M | $10.64M | $33.80M | $32.42M | $67.39M |
| Current liabilities | $2.29M | $18.03M | $10.77M | $7.07M | $30.98M |
| Total liabilities | $2.29M | $18.10M | $21.32M | $15.72M | $31.85M |
| Shareholders' equity | $2.87M | -$7.47M | $12.07M | $16.70M | $35.54M |
| Shares outstanding | 42.28M | 421,124 | 2.99M | 2.08M | 2.07M |
| Cash flow statement | |||||
| Operating cash flow | -$6.73M | -$2.60M | -$7.63M | -$12.80M | -$11.86M |
| Capital expenditure | — | $24,587 | — | — | — |
| Free cash flow | — | -$2.63M | — | — | — |
| Investing cash flow | — | -$24,587 | — | — | — |
| Financing cash flow | $8.16M | -$7.00M | $11.54M | -$1.62M | $18.57M |
| Depreciation & amortization | — | $2.83M | $3.28M | $5.60M | $6.88M |
| Stock-based compensation | $304,634 | $197,215 | $417,230 | $1.20M | $1.31M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.